Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype. [electronic resource]
Producer: 20130319Description: e40439 p. digitalISSN:- 1932-6203
- Adaptor Proteins, Signal Transducing -- metabolism
- Animals
- Apoptosis -- drug effects
- Benzimidazoles -- pharmacology
- Cell Cycle Proteins
- Cell Line, Tumor
- Cell Survival -- drug effects
- Drug Resistance, Neoplasm -- drug effects
- Drug Synergism
- GTP-Binding Protein alpha Subunits -- genetics
- GTP-Binding Protein alpha Subunits, Gq-G11
- Genotype
- Humans
- Mechanistic Target of Rapamycin Complex 2
- Melanoma -- drug therapy
- Mice
- Mitogen-Activated Protein Kinase Kinases -- antagonists & inhibitors
- Models, Biological
- Morpholines -- pharmacology
- Multiprotein Complexes -- metabolism
- Mutation -- genetics
- Myeloid Cell Leukemia Sequence 1 Protein
- Phosphoproteins -- metabolism
- Phosphorylation -- drug effects
- Protein Kinase Inhibitors -- pharmacology
- Proto-Oncogene Proteins B-raf -- genetics
- Proto-Oncogene Proteins c-akt -- metabolism
- Proto-Oncogene Proteins c-bcl-2 -- metabolism
- Receptor, IGF Type 1 -- metabolism
- TOR Serine-Threonine Kinases -- antagonists & inhibitors
- Uveal Neoplasms -- drug therapy
- Xenograft Model Antitumor Assays
- Uveal Melanoma
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.